Handelsbanken Fonder Ab Rubius Therapeutics, Inc. Transaction History

Handelsbanken Fonder Ab

  • $25.3 Billion
  • Q3 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 03, 2022
SELL
$0.79 - $5.98 $11,771 - $89,102
-14,900 Closed
0 $0
Q4 2021

Feb 08, 2022
BUY
$9.68 - $17.74 $26,136 - $47,897
2,700 Added 22.13%
14,900 $144,000
Q2 2021

Aug 03, 2021
BUY
$22.26 - $28.43 $271,572 - $346,846
12,200 New
12,200 $298,000

Others Institutions Holding RUBY

# of Institutions
2
Shares Held
325
Call Options Held
0
Put Options Held
0
View Full List

About Rubius Therapeutics, Inc.

RUBY Quotes by TradingView
  • Ticker RUBY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,357,000
  • Description
  • Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...
More about RUBY
Track This Portfolio

Track Handelsbanken Fonder Ab Portfolio

Follow Handelsbanken Fonder Ab and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email